Show
Sort by
-
- Journal Article
- A1
- open access
Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia : experience of the European LeukemiaNet MRD Working Party
-
- Journal Article
- A1
- open access
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML : the HOVON-SAKK-132 trial
-
- Journal Article
- A1
- open access
TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment
-
RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML
-
Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients
-
Comparison between FLT3-ITD measurements based on RNA and DNA of childhood myeloid leukemia samples
-
Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)-AML : results from an international retrospective study by the International Berlin-Frankfurt-Münster study group
-
The relevance of stem cell load at diagnosis for the development of relapse in pediatric acute myeloid leukemia
-
Clinical impact of additional cytogenetic aberrations, cKIT- and RAS mutations and other factors in pediatric t(8;21)-AML
-
The prognostic value of leukemic stem cells in pediatric AML